Introduction
============

CTL-associated antigen 4 (CTLA-4 \[CD152\]) is a CD28 homologue expressed on activated T cells and, upon interaction with CD80 or CD86 on APCs, exerts a downregulatory or attenuating effect on T cell--mediated immune responses [1](#R1){ref-type="bib"} [2](#R2){ref-type="bib"}. Accumulating evidence indicates that it also plays an important role in immunologic self-tolerance in the periphery. CTLA-4--deficient mice, for example, develop a severe lymphoproliferative disorder and die from autoimmune-like disease within 1 mo after birth [3](#R3){ref-type="bib"} [4](#R4){ref-type="bib"}. Administration of anti--CTLA-4 Ab exacerbated autoimmune responses in a murine model of multiple sclerosis or insulin-dependent diabetes mellitus (IDDM \[5--7\]), enhanced tumor immunity [8](#R8){ref-type="bib"}, or prevented the induction of immunologic tolerance to concurrently administered non--self-antigens [9](#R9){ref-type="bib"}. However, it is uncertain whether these findings can be explained by the current notion that CTLA-4 transduces negative signals to activated effector T cells [1](#R1){ref-type="bib"} [2](#R2){ref-type="bib"} [10](#R10){ref-type="bib"}. In this report, we show another possible role of CTLA-4 in immunologic self-tolerance.

There is accumulating evidence that, in addition to clonal deletion or anergy, T cell--mediated dominant control of self-reactive T cells represents one mechanism for maintaining immunologic self-tolerance [11](#R11){ref-type="bib"}. For example, removal of a subpopulation of CD4^+^ T cells leads to spontaneous development of various T cell--mediated autoimmune diseases (e.g., thyroiditis, gastritis, and insulin-dependent diabetes mellitus) in otherwise normal rodents, and reconstitution of the removed population prevents the autoimmune development [12](#R12){ref-type="bib"} [13](#R13){ref-type="bib"}. Elimination of CD25^+^CD4^+^ T cells (which constitute 5--10% of peripheral CD4^+^ T cells in normal naive mice), for example, elicits various autoimmune diseases in genetically susceptible strains of mice [14](#R14){ref-type="bib"} [15](#R15){ref-type="bib"} [16](#R16){ref-type="bib"} [17](#R17){ref-type="bib"} [18](#R18){ref-type="bib"} [19](#R19){ref-type="bib"} [20](#R20){ref-type="bib"}. The elimination also evokes potent tumor immunity in otherwise nonresponding animals [17](#R17){ref-type="bib"}. These in vivo and in vitro findings, especially similar effects of CTLA-4 blockade and CD25^+^ T cell elimination on autoimmunity and tumor immunity, have led us to examine possible involvement of CTLA-4 in T cell--mediated immunoregulation.

Here, we demonstrate that CTLA-4 is indeed a key costimulatory molecule for activating CD25^+^CD4^+^ regulatory T cells to exert suppression and thereby to control self-reactive T cells, and that in vivo blockade of CTLA-4 expressed on the regulatory T cells suffices to break natural self-tolerance and elicit pathological autoimmunity.

Materials and Methods
=====================

Mice.
-----

8-wk-old BALB/c, BALB/c athymic nude, or C57BL/6 (B6) mice were purchased from SLC. DO11.10 transgenic mice expressing transgenic TCR specific for an OVA peptide were the gift of Dr. D.Y. Loh (Roche Japan, Kamakura, Japan). CTLA-4-- or CD28-deficient mice on the B6 background were described previously [3](#R3){ref-type="bib"} [21](#R21){ref-type="bib"}. All these mice were maintained in our animal facility and cared for in accordance with the institutional guidelines for animal welfare.

In Vivo Injection of mAb.
-------------------------

The hybridoma cells secreting hamster anti--CTLA-4 mAb (UC10-4F10-11) were a gift from Dr. J. Bluestone (University of Chicago, Chicago, IL \[22\]). The Ab was purified from ascites in SCID mice using protein A columns [22](#R22){ref-type="bib"} [23](#R23){ref-type="bib"}. Rat anti-CD25 mAb (PC61) was purified from ascites in SCID mice by 40% ammonium sulfate precipitation twice as described previously [17](#R17){ref-type="bib"}.

Serologic Analysis.
-------------------

For flow cytometric analysis, 10^6^ cells were incubated with FITC- or PE-labeled or biotinylated mAbs, with RPE--CyChrome 5--streptavidin (Dako) as the secondary reagent for biotinylated Abs, and analyzed by flow cytometry (Epics-XL; Beckman Coulter). FITC-labeled or biotinylated anti-CD25 mAb (7D4), FITC--anti-CD4 mAb (H129.19), PE-labeled anti--CTLA-4 mAb (UC10-4F10-11), and anti-FcR mAb (2.4G2) were purchased from BD PharMingen.

Cell Sorting.
-------------

Spleen and lymph node cell suspensions prepared from 8-wk-old BALB/c, DO11.10, or CD28-deficient mice or 2--3-wk-old CTLA-4--deficient mice were stained with FITC--anti-CD25 mAb (7D4) and PE--anti-CD4 mAb (H129.19; BD PharMingen) and sorted by a FACS^®^ (Epics-Elite; Beckman Coulter), as described previously [18](#R18){ref-type="bib"} [19](#R19){ref-type="bib"}. Purity of the CD25^+^ or CD25^−^CD4^+^ population was \>90% and ∼99%, respectively.

In Vitro Proliferation Assay.
-----------------------------

Lymph node and spleen T cells (2.0--2.5 × 10^4^), sorted as described above, and red blood cell--lysed, x-irradiated (20 Gy) BALB/c spleen cells (5 × 10^4^) as APCs were cultured for 3 d in 96-well round-bottomed plates (Costar) in RPMI 1640 medium supplemented with 10% FCS (GIBCO BRL), penicillin (100 U/ml), streptomycin (100 μg/ml), and 50 μM 2-ME. Anti--CD3 mAb (145-2C[11](#R11){ref-type="bib"}; Cedarlane Laboratories) at a final concentration of 10 μg/ml or Con A at 1 μg/ml were added to the culture for stimulation [18](#R18){ref-type="bib"} [19](#R19){ref-type="bib"}. Incorporation of ^3^H-TdR (1 μCi/well; Dupont) by proliferating lymphocytes during the last 6 h of the culture was measured [18](#R18){ref-type="bib"} [19](#R19){ref-type="bib"}. Fab fragments of anti--CTLA-4 mAb or normal hamster IgG (Cortex Biochem, Inc.) were prepared by digesting these Abs with immobilized papain (Pierce Chemical Co.) according to the manufacturer\'s instruction.

Histology and Serology.
-----------------------

Stomachs and other organs were fixed with 10% formalin and processed for hematoxylin and eosin staining. Serum titers of autoantibodies specific for the gastric parietal cells were assayed by ELISA [14](#R14){ref-type="bib"} [15](#R15){ref-type="bib"}. Gastritis was graded 0--2+ depending on macroscopic and histological severity, as described previously [12](#R12){ref-type="bib"} [14](#R14){ref-type="bib"} [15](#R15){ref-type="bib"}.

Results and Discussion
======================

Constitutive Expression of CTLA-4 on CD25^+^CD4^+^ T Cells in Normal Naive Mice.
--------------------------------------------------------------------------------

CTLA-4 is supposed to be expressed on T cells only after activation [1](#R1){ref-type="bib"} [2](#R2){ref-type="bib"}. However, in the peripheral lymphoid organs of normal naive mice, flow cytometric analysis of cell surface as well as cytoplasmic expression of CTLA-4 revealed that the molecule was constitutively expressed on/in CD25^+^CD4^+^ T cells but not on/in CD25^−^CD4^+^ T cells (or CD8^+^ T cells; data not shown) whether the mice were raised in a specific pathogen-free condition or not ([Fig. 1](#F1){ref-type="fig"}). Both populations expressed high levels of CTLA-4 upon in vitro T cell stimulation (for example, with Con A). The two populations showed no difference in their expression levels of CD28, which appears to be constitutively expressed on all murine T cells [24](#R24){ref-type="bib"}.

Induction of Autoimmune Disease in Normal Mice by Anti--CTLA-4 Ab Treatment.
----------------------------------------------------------------------------

To determine the role of CTLA-4 expressed on CD25^+^CD4^+^ T cells in self-tolerance and autoimmunity, we administered purified anti--CTLA-4 mAb (0.8 or 0.1 mg), anti-CD25 mAb (1 mg), or the mixture of anti--CTLA-4 mAb (0.1 mg) and anti-CD25 mAb (1 mg) once a week three times to normal BALB/c mice from the age of 10 d, and examined the mice at 3 mo of age ([17](#R17){ref-type="bib"} [25](#R25){ref-type="bib"}; [Fig. 2](#F2){ref-type="fig"}). All the mice treated with high doses (0.8 mg/injection) of anti--CTLA-4 mAb spontaneously developed histologically and serologically evident autoimmune gastritis and some other autoimmune diseases (i.e., oophoritis or mild sialoadenitis, in one mouse each) ([12](#R12){ref-type="bib"} [14](#R14){ref-type="bib"} [15](#R15){ref-type="bib"}; [Fig. 2a](#F2){ref-type="fig"} [Fig. b](#F2){ref-type="fig"} [Fig. c](#F2){ref-type="fig"}). Low doses of anti--CTLA-4 mAb or anti-CD25 mAb alone induced only low titers of autoantibody without histological evidence of autoimmune disease, whereas treatment with the mixture of the two mAbs produced autoimmune gastritis in the majority (∼85%) of mice.

Administration of anti-CTLA-4 mAb did not significantly alter the number of CD25^+^CD4^+^ T cells or the ratio of CD25^+^ T cells among CD4^+^ T cells, whereas administration of anti-CD25 mAb or the mixed mAbs reduced CD25^+^CD4^+^ T cells to 10--30% of the controls ([Fig. 2](#F2){ref-type="fig"} D). For example, 1 wk after the last treatment, percentages of CD25^+^ cells among the CD4^+^ cells in the lymph nodes were 7.2 ± 0.3% in the control mice, 10.1 ± 0.30% and 9.6 ± 0.26% in the high- or low-dose anti--CTLA-4 mAb--treated mice, respectively, 0.93 ± 0.15% in the anti--CD25 mAb--treated mice, and 2.1 ± 0.1% in the mixed mAb--treated mice (*n* = 3 for each).

The affected gastric mucosa was characterized by loss and damage of the parietal cells and the chief cells, compensatory hyperplasia of mucous-secreting cells, and a massive infiltration of mononuclear cells ([Fig. 2b](#F2){ref-type="fig"} and [Fig. c](#F2){ref-type="fig"}). The lesion was immunopathologically similar to human autoimmune gastritis with pernicious anemia [26](#R26){ref-type="bib"}. Furthermore, the gastritis thus induced could be adoptively transferred to naive BALB/c athymic nude mice by spleen cells from gastritis-bearing BALB/c mice, indicating that the lesion was a result of a bona fide autoimmune disease ([Fig. 2](#F2){ref-type="fig"} E).

Thus, autoimmune diseases similar to those produced by elimination of CD25^+^CD4^+^ T cells could be elicited in normal mice by blockade of CTLA-4 with high-dose anti--CTLA-4 Ab, or reduction of CD25^+^CD4^+^ T cells accompanied by CTLA-4 blockade on the residual T cells with low-dose anti--CTLA-4 Ab [14](#R14){ref-type="bib"} [15](#R15){ref-type="bib"}. In the latter treatment, it is plausible that reduction of CD25^+^CD4^+^ T cells might have partially triggered the activation of autoimmune effector T cells, which might then be further activated by the blockade of CTLA-4 expressed on them. Nevertheless, successful autoimmune induction by CTLA-4 blockade alone without reduction of CD25^+^CD4^+^ T cells ([Fig. 2](#F2){ref-type="fig"} D), together with the constitutive expression of CTLA-4 on normal CD25^+^CD4^+^ T cells ([Fig. 1](#F1){ref-type="fig"}), indicates that the blockade of CTLA-4 on the CD25^+^CD4^+^ T cells is most likely the triggering mechanism of this autoimmunity.

Role of CTLA-4 in CD25^+^CD4^+^ T Cell--mediated Suppression In Vitro.
----------------------------------------------------------------------

CD25^+^CD4^+^ T cells present in normal naive mice exhibited no proliferative response to TCR stimulation, whereas, upon TCR stimulation, they potently suppressed the activation and proliferation of other T cells, as reported previously ([18](#R18){ref-type="bib"} [19](#R19){ref-type="bib"} [20](#R20){ref-type="bib"} [27](#R27){ref-type="bib"}; [Fig. 3](#F3){ref-type="fig"}). To examine the possible role of CTLA-4 in this natural anergy and suppression, we added anti--CTLA-4 Ab, its Fab fragments, or control hamster Ab to 3-d cultures of CD25^+^CD4^+^ T cells or CD25^−^CD4^+^ T cells (purified as shown in [Fig. 1](#F1){ref-type="fig"}), or a mixture of an equal number of the two populations, and stimulated the cultures with Con A ([Fig. 3](#F3){ref-type="fig"} A) or soluble anti-CD3 mAb ([Fig. 3](#F3){ref-type="fig"} B) along with APCs. Anti-FcγII/III receptor (FcR \[CD16/CD32\]) mAb was also added to some cultures to inhibit anti--CTLA-4 mAbs from attaching to FcRs on APCs, thereby preventing the Abs from cross-linking CTLA-4 and transducing signals [22](#R22){ref-type="bib"} [23](#R23){ref-type="bib"}. In these experiments, intact anti--CTLA-4 mAb, especially in the presence of anti-FcR mAb, significantly neutralized CD25^+^CD4^+^ T cell--mediated suppression of the activation and proliferation of CD25^−^CD4^+^ T cells ([Fig. 3](#F3){ref-type="fig"} A). Although others reported no significant effect of anti--CTLA-4 mAb in a similar cell culture system [20](#R20){ref-type="bib"}, the discrepancy could be attributed to the concentration of anti--CTLA-4 mAb in the culture; i.e., with a high dose (100 μg/ml) of anti--CTLA-4 mAb, as shown here, the majority of CTLA-4 molecules could be blocked rather than cross-linked by the Ab attached to FcR on APCs. This blocking effect was further supported by the result that Fab--anti--CTLA-4 mAb, which is presumably able to block but unable to cross-link CTLA-4 [22](#R22){ref-type="bib"} [23](#R23){ref-type="bib"}, more efficiently abrogated the suppression in a dose-dependent fashion ([Fig. 3A](#F3){ref-type="fig"} and [Fig. B](#F3){ref-type="fig"}). In addition to these polyclonal T cell activations, the Fab fragments also neutralized CD25^+^CD4^+^ T cell--mediated control of antigen-specific activation and proliferation of OVA-specific T cells from DO11.10 transgenic mice ([18](#R18){ref-type="bib"} [19](#R19){ref-type="bib"}; [Fig. 3](#F3){ref-type="fig"} C). On the other hand, intact or Fab--anti--CTLA-4 mAb did not significantly affect the responses of CD25^−^CD4^+^ T cells or break the anergic state of CD25^+^CD4^+^ T cells ([Fig. 3A--C](#F3){ref-type="fig"}).

To determine more definitely the role of CTLA-4 on CD25^+^CD4^+^ T cells, we used CTLA-4--deficient mice. CD25^+^CD4^+^ T cells from normal mice efficiently suppressed CD25^−^CD4^+^ T cells from CTLA-4--deficient mice, and Fab--anti-CTLA-4 mAb abrogated this suppression in a dose-dependent fashion ([Fig. 3](#F3){ref-type="fig"} D). In the reciprocal combination, CTLA-4--deficient CD25^+^CD4^+^ T cells also exhibited weak suppressive activity (∼50% in percentage suppression compared with \>95% by normal CD25^+^ CD4^+^ T cells at 1:1 mixing with CD25^−^CD4^+^ T cells). The CD25^+^ T cells constituted up to 30% of CD4^+^ T cells in the enlarged spleens of CTLA-4--deficient mice and appeared to be different from normal CD25^+^CD4^+^ T cells in including a large number of abnormally activated T cells [3](#R3){ref-type="bib"}. It remains to be determined whether this weak suppressive activity could be peculiar to CTLA-4--deficient CD25^+^CD4^+^ T cells (e.g., because of compensatory activation of other genes encoding molecules concerned with the suppression). Indeed, blockade of certain other cell surface molecules could abrogate the suppressive activity of CTLA-4--deficient as well as normal CD25^+^CD4^+^ T cells (our unpublished results). Despite this possibility, the results in [Fig. 3A--D](#F3){ref-type="fig"}, when taken together, indicate that CTLA-4 expressed on CD25^+^CD4^+^ regulatory T cells is critically involved in this in vitro T cell--mediated immunoregulation.

Activation of T cells usually requires a costimulatory signal through CD28 in addition to the TCR signal [24](#R24){ref-type="bib"}. However, CD25^+^CD4^+^ T cells from CD28-deficient mice exhibited a potent suppressive activity ([Fig. 3](#F3){ref-type="fig"} E). This indicates that CD28 on CD25^+^CD4^+^ T cells ([Fig. 1](#F1){ref-type="fig"}) is dispensable for the CD25^+^CD4^+^ T cell--mediated suppression, even if CD28 deficiency might affect the development of regulatory T cells (e.g., the number of CD25^+^ CD4^+^ T cells in CD28-deficient B6 mice reduced to ∼20% of normal B6 mice; our unpublished data) or their level of CTLA-4 expression [28](#R28){ref-type="bib"} [29](#R29){ref-type="bib"}. On the other hand, we have shown previously that ligation of the CD28 molecule with anti-CD28 Ab, in conjunction with TCR stimulation, can break the naturally anergic state of CD25^+^ CD4^+^ T cells and simultaneously abolish their suppressive activity [18](#R18){ref-type="bib"} [19](#R19){ref-type="bib"}. These findings collectively imply unique roles for CTLA-4 and CD28 in CD25^+^CD4^+^ regulatory T cells; i.e., costimulation via CTLA-4 may activate the regulatory T cells to exert suppression, whereas costimulation via CD28 may attenuate their suppressive activity. The balance between the two signals in a particular CD25^+^CD4^+^ regulatory T cell may be critical in determining its activation threshold and/or its suppressive activity. Furthermore, the balance between regulatory T cells activated through CTLA-4 and effector T cells activated through CD28 may contribute to determining the threshold or the magnitude of a particular immune response.

It remains to be determined how CD25^+^CD4^+^ regulatory T cells suppressively control other T cells upon stimulation via CTLA-4 and TCR. Although TGF-β possibly secreted by TCR- and CTLA-4--stimulated T cells may contribute to attenuating activated T cells, as shown by others [30](#R30){ref-type="bib"}, anergic/suppressive CD25^+^CD4^+^ T cells stimulated via CTLA-4 and TCR did not secrete detectable amounts of TGF-β, and the suppression was not abrogated by adding neutralizing anti--TGF-β Ab to the culture ([18](#R18){ref-type="bib"} [20](#R20){ref-type="bib"}; our unpublished data). As a possible mechanism of the suppression, CD25^+^CD4^+^ T cells stimulated via CTLA-4 and TCR may physically interfere with the interaction of other T cells with APCs by competing for the costimulatory molecules on APCs, as they are predominantly expressing CTLA-4 (which has a higher affinity for CD80/CD86 than CD28 \[22\]) and various adhesion molecules (such as intercellular adhesion molecule \[ICAM\]-1, LFA-1, and CD2) at high levels [18](#R18){ref-type="bib"} [19](#R19){ref-type="bib"} [20](#R20){ref-type="bib"}. Alternatively, the signals via TCR and CTLA-4 may activate CD25^+^CD4^+^ T cells to deliver to other T cells a negative signal for activation and proliferation. These possibilities are currently under investigation.

There are accumulating demonstrations that CTLA-4 deficiency or blockade induces or exacerbates autoimmunity, enhances tumor immunity, or prevents induction of immunologic tolerance [4](#R4){ref-type="bib"} [5](#R5){ref-type="bib"} [6](#R6){ref-type="bib"} [7](#R7){ref-type="bib"} [8](#R8){ref-type="bib"} [9](#R9){ref-type="bib"}. These effects of CTLA-4 deficiency or blockade have been largely explained as a hindrance of CTLA-4--transduced negative signals to activated T cells mediating immune responses [1](#R1){ref-type="bib"} [2](#R2){ref-type="bib"}. However, our present in vivo and in vitro results indicate that the effects can also be attributed, at least in part, to the blockade of CTLA-4 molecules expressed on CD25^+^CD4^+^ regulatory T cells and consequent interference with T cell--mediated immunoregulation. CTLA-4 also appears to play a similar role in the function of regulatory T cells that control inflammatory bowel disease [31](#R31){ref-type="bib"}. Exploitation of this unique role of CTLA-4 in immunologic self-tolerance would help to develop novel strategies for treating or preventing autoimmune disease, enhancing immunity to autologous tumor cells, or inducing tolerance to allotransplants.
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![Constitutive expression of CTLA-4 on CD25^+^CD4^+^ T cells in normal naive mice. Lymph node and spleen cell suspensions prepared from a 2-mo-old BALB/c mouse were stained with FITC--anti-CD4 Ab and biotinylated anti-CD25 Ab with RPE-CyChrome 5--conjugated streptavidin as the secondary reagent. Cells enclosed with rectangles were sorted as CD25^+^ or CD25^−^4^+^ T cells. The sorted cells were stained for 2 h at 37°C with PE-conjugated anti--CTLA-4 Ab or PE-conjugated anti--human CD4 Ab as a staining control, and are shown as histograms (solid lines or shaded areas, respectively; the abscissa shows the staining intensity on a logarithmic scale and the ordinate shows the number of cells on an arbitrary scale) (reference 28). The sorted cells were also cultured with Con A (1 μg/ml) at 37°C for 24 h and incubated for the last 2 h with PE--anti--CTLA-4 Ab. CD28 expression on CD25^+^ or CD25^−^4^+^ T cells is shown as histograms by staining the cells with PE--anti-CD28 Ab. A representative result of five independent experiments is shown. Stim., stimulation.](JEM000231.f1){#F1}

###### 

Induction of autoimmune disease in BALB/c mice by administration of anti--CTLA-4 Ab with or without anti-CD25 Ab. (A) BALB/c mice were injected intraperitoneally with indicated doses of purified anti--CTLA-4 mAb, anti-CD25 mAb, a mixture of the two mAbs, or control rat Ig once a week three times from the age of 10 d, and were examined at 3 mo of age for histological and/or serological development of autoimmune disease. The gastric lesion was histologically graded as macroscopically and histologically evident grade-2 gastritis (black circle), histologically evident grade-1 gastritis (gray circle), or intact gastric mucosa (white circle; for detailed grading, see references 12, 14, 15). Titers of antiparietal cell autoantibodies were assessed by ELISA. The gastric mucosa of a grade-2 gastritis in a mouse treated with anti--CTLA-4 mAb is shown in B, and the intact gastric mucosa of a mouse treated with rat Ig is shown in C. Samples were stained with hematoxylin and eosin (original magnification: ×25). (D) Composition of T cell subpopulations defined by the expression of CD4 and CD25 7 d after the last Ab treatment. Lymph node cells were stained with PE--anti-CD4 mAb and FITC--anti-CD25 mAb, 7D4, another anti-CD25 mAb with different epitope specificity, as described previously (reference 18). A representative staining of three independent experiments is shown. (E) Spleen cells (5 × 10^7^) from anti--CTLA-4 mAb-- or mixed mAb--treated mice with gastritis or from rat Ig--treated mice were transferred intravenously to BALB/c athymic nude mice, which were histologically and serologically examined 2 mo later. Black circle, macroscopically and histologically evident grade-2 gastritis; gray circle, histologically evident grade-1 gastritis; white circle, intact gastric mucosa. A representative result of more than three independent experiments is shown. The means of duplicate cultures are shown, and the SEM was within 10% of the mean for each experiment.
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![Key role of CTLA-4 expressed on CD25^+^CD4^+^ regulatory T cells in downregulating the activation and proliferation of other T cells. (A) Anti--CTLA-4 mAb (100 μg/ml) or control hamster Ab with or without anti-FcR mAb (10 μg/ml) or Fab--anti-CTLA-4 mAb (100 μg/ml) was added to the culture of CD25^+^ or CD25^−^CD4^+^ T cells purified from BALB/c spleen and lymph node cells (as shown in [Fig. 1](#F1){ref-type="fig"}), or these two populations were mixed at a 1:1 ratio. The culture was stimulated for 3 d with Con A (1 μg/ml) along with irradiated BALB/c spleen cells as APCs. Incorporation of ^3^H-TdR during the last 6 h of the culture is shown as the degree of proliferation. Background counts in the wells with APCs alone were always \<1,500 cpm in these experiments and those below. α, anti-. (B) CD25^+^ or CD25^−^CD4^+^ T cells or a 1:1 mixture of the two populations were stimulated with anti-CD3 mAb (10 μg/ml) in the presence of Fab--anti--CTLA-4 mAb at various concentrations (black symbols) or control Fab--hamster IgG at 300 μg/ml (white symbols). (C) CD25^+^ or CD25^−^CD4^+^ T cells or two populations mixed at an equal ratio, purified from the spleens of DO11.10 transgenic mice, were cultured for 3 d with 0.1 μM OVA-P(323--339) in the presence of Fab--anti--CTLA-4 mAb or control Fab--hamster IgG at 100 μg/ml. α, anti-. (D) CD25^−^CD4^+^ T cells prepared from 3-wk-old CTLA-4--deficient (CTLA-4^−/^−) B6 mice or a 1:1 mixture of these cells with CD25^+^CD4^+^ T cells from 2-mo-old normal B6 mice was stimulated with anti-CD3 mAb for 3 d in the presence of Fab--anti--CTLA-4 mAb at indicated concentrations. The counts of CTLA-4--deficient CD25^−^CD4^+^ T cells cultured without stimulation were background levels (i.e., \<2,000 cpm). α, anti-. (E) CD25^+^CD4^+^ T cells prepared from CD28-deficient (CD28^−/^−) B6 mice or normal B6 mice were mixed with an equal number of CD25^−^CD4^+^ T cells from normal B6 mice and stimulated with anti-CD3 mAb for 3 d. A representative result of more than three independent experiments is shown. The means of duplicate cultures are shown, and the SEM was always with 10% of the mean for each experiment.](JEM000231.f3){#F3}
